Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition
The deal is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-acting treatments for serious immune-mediated diseases. The post Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition appeared first on GEN - Genetic Engineering and Biotechnology News .
Argenx has agreed to acquire Unnatural Products (UNP) for up to $1.15 billion, expanding its immunology capabilities. The deal is designed to combine UNP's macrocyclic peptide discovery platform with Argenx's immunology innovation expertise, enabling the development of oral or long-acting treatments for serious immune-mediated diseases.
This acquisition transforms Argenx from a minority stakeholder in UNP to the sole owner of its shares. Argenx aims to diversify its pipeline beyond its antibody-based portfolio, which includes blockbuster drugs Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo. The acquisition marks Argenx's next chapter, with CEO Karen Massey emphasizing the company's ambition to be the leading immunology innovation company.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
